Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989572 · ClinicalTrials.gov registry record · Phase 3
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 815
- Enrollment target
NCT01989572: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT01989572 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 815 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01989572, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 815 participants
- Enrollment target
Study Summary
This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has been removed by surgery. Sargramostim may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether yeast derived sargramostim and vaccine therapy are more effective alone or together in preventing recurrence of melanoma.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Sargramostim
- BIOLOGICAL Tyrosinase Peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 815 participants |
| Start Date | 2000-02-23 |
| Est. Completion | 2013-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01989572
The ClinicalTrials.gov registry entry for NCT01989572 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 815 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01989572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01989572 about?
NCT01989572 is a clinical study titled "Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery". This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has been removed by surgery. Sargramostim may stimulate the immune system in d...
What is the current status of trial NCT01989572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 815 participants. The study started on 2000-02-23. Estimated completion is 2013-01-31.
What interventions are being tested in trial NCT01989572?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Sargramostim (BIOLOGICAL), Tyrosinase Peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT01989572?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.